Medical Devices Late Stage Investors & VC Firms
247 firms in this list, with a median first check of $1.1M. 58 of them lead rounds. Generated from verified public data and updated continuously.
Concord Health Partners
SummitLate Stage
14 people
Yuanta Investment
SeoulSeed–Late Stage$1M – $15M
20 people
Tin Alley Ventures
MelbourneSeed–Late Stage
13 people
GEOC
ShanghaiSeed–Late Stage$3M – $10M
10 people
Maxpro Ventures
TaipeiSeed–Late Stage
7 people
Sycamore Ventures
PrincetonGrowth–Late Stage$5M – $20M
13 people
Prospect Venture Partners
Menlo ParkSeed–Late Stage$3M – $5M
3 people
TVM Capital
MunichSeed–Late Stage$1.1M – $16.2M
10 people
Arc Angels
AucklandPre-Seed–Late Stage
Texas Ventures
HoustonSeed–Late Stage
6 people
Corner Ventures
New YorkSeed–Late Stage
15 people
ALIVE Israel HealthTech Fund
SavyonSeed–Late Stage
10 people
Endeavour Vision
GenevaLate Stage
6 people
Shepherd Ventures
San DiegoSeries A–Late Stage$750K – $3M
6 people
Partners Investment Co. Ltd.
SeoulSeries A–Late Stage
11 people
Fresenius Medical Care Ventures
Bad HomburgSeed–Late Stage
7 people
BPEA EQT
Growth–Late Stage$50M – $3B
8 people
Access Biotechnology
New YorkSeed–Late Stage
3 people
Evidity Health Capital
New YorkGrowth–Late Stage$5M
5 people
Rosetta Capital Ltd.
OxfordGrowth–Late Stage
8 people
Avego BioScience Capital
AlpharettaSeries A–Late Stage
2 people
Cycad Group LLC
Santa BarbaraSeed–Late Stage
4 people
Target Partners
MunichSeed–Late Stage$1.1M – $3.2M
7 people
Toledo Capital AG
ZürichSeed–Late Stage
12 people
Related lists
Medical Devices Investors & VC Firms (1714)Late Stage Investors & VC Firms (1710)Medical Devices Seed Investors & VC Firms (1369)Medical Devices Series A Investors & VC Firms (1174)Medical Devices Investors & VC Firms in North America (1135)Medical Devices Investors & VC Firms in United States (1053)Late Stage Investors & VC Firms in North America (915)Late Stage Investors & VC Firms in United States (814)Medical Devices Investors & VC Firms in Europe (687)Late Stage Investors & VC Firms in Global (566)
Data sourced from public filings and firms' own websites — see our methodology.















































































